Last reviewed · How we verify
A Double-blind, Placebo-controlled, Therapeutic Trial With Antitussive Drug-Dextromethorphan: Aimed to Determine Its Therapeutic Effect in Patients With Rheumatoid Arthritis
Rheumatoid arthritis were randomized to a 6-month treatment of oral dextromethorphan hydrobromide or placebo as an add-on therapy to traditional disease-modifying anti-rheumatic drugs (DMARDs). Disease activity were assessed.
Details
| Lead sponsor | Taichung Veterans General Hospital |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 48 |
| Start date | 2010-01 |
| Completion | 2012-09 |
Conditions
- Rheumatoid Arthritis
Interventions
- Dextromethorphan hydrobromide
Primary outcomes
- Good European League Against Rheumatism (EULAR) Therapeutic Response Rate — 6 months